Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company’s development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; and Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer; Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in phase 2 clinical trial for colorectal cancer; and Zimberelimab, an anti-PD-1 antibody. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer; and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.
HIF-2alpha Promise | Arcus Biosciences' HIF-2alpha inhibitor program, led by casdatifan, shows potential in renal cell carcinoma treatment, driving investor interest and analyst optimism |
Financial Challenges | Despite promising pipeline, Arcus operates at a loss with negative EPS projections, reflecting typical biotech sector challenges and need for careful financial management |
Competitive Edge | Explore how Arcus positions itself in the oncology space, leveraging combination therapies and benefiting from setbacks in competing anti-TIGIT programs |
Future Catalysts | Analyst price targets range from $14 to $29, with upcoming clinical data readouts and trial results potentially driving significant stock performance in 2025-2026 |
Metrics to compare | RCUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRCUSPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.7x | −1.2x | −0.5x | |
PEG Ratio | 4.05 | −0.05 | 0.00 | |
Price/Book | 2.0x | 1.7x | 2.6x | |
Price / LTM Sales | 4.2x | 8.3x | 3.3x | |
Upside (Analyst Target) | 140.8% | 279.7% | 38.7% | |
Fair Value Upside | Unlock | 27.7% | 5.0% | Unlock |